Beyond his social media platform, he wants to go back to college to become a social worker to work with people with ...

I had the pleasure of attending a Netflix event around the WoW documentary The Remarkable Life of Ibelin last year—one that ...

ATH434 is designed to reduce α-synuclein aggregation and oxidative stress by binding to and redistributing excess loosely bound iron in the brain.

Discover Ocugen's Q1 2025 earnings insights, focusing on gene therapy advancements, key clinical trials, and financial updates.

Digital PCR to simultaneously detect SMN1 gene defects and the number of SMN2 copies to diagnose SMA matches standard methods ...

A 17-year-old has become the world's youngest person ever diagnosed with Alzheimer’s disease, challenging long-standing ...

Alterity Therapeutics Limited’s ATHE share price has surged by 8.51%, which has investors questioning if this is right time to sell.

Researchers presented an exploratory analysis comparing OCT biomarkers in a Phase 1b study of ONL1204 in patients with ...

Veterans, including some from Illinois, were exposed to lethal radiation at a military base in Nevada. Because their work was classified the VA will not provide ...

The consensus rating for Ocugen is Buy, derived from 4 analyst ratings. An average one-year price target of $7.25 implies a ...

A Plymouth man is facing animal cruelty charges after an investigation by state police. Police say Preston L. Branagan was ...

Investigators developed a novel severity scoring system for age-related macular degeneration that can generate distinct scores for exudative and nonexudative AMD.